A

Arthritis and Osteoporosis Consultants of the Carolinas | Midtown Medical Plaza

Research site

(Unclaimed)

Location

1918 Randolph Road Suite 600, Charlotte, North Carolina, United States of America

Site insights

Top conditions

Top treatments

Dazodalibep

Tanezumab

Naproxen

Ibuprofen

RSLV-132

SAR441566

Celecoxib

Baricitinib

Ixekizumab

Deucravacitinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 14 total trials

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Primary Objective:To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom stateSecon...

Active, not recruiting

Sjögren's Syndrome (SS)

Drug: Dazodalibep

Drug: Placebo

A Study of RSLV-132 in Females With Sjögren's Disease

The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132. The m...

Enrolling

Primary Sjögren Syndrome

Drug: RSLV-132

Drug: Placebo

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Active, not recruiting

Systemic Lupus Erythematosus

Other: Placebo

Drug: Deucravacitinib

Locations recently updated

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Primary Objective:To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe...

Active, not recruiting

Sjogren's Syndrome

Drug: Dazodalibep

Drug: Placebo